Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 3/20 | 0.35 |
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21240537 | 0.89 | NOS1 (0.36) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL29578158 | 0.89 | NOS1 (0.36) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL30045100 | 0.89 | NOS1 (0.38) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL20331789 | 0.89 | NOS1 (0.38) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL20331791 | 0.89 | PDE4B (0.35) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL20331483 | 0.89 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL29578278 | 0.89 | PDE4B (0.45) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL20331796 | 0.88 | NOS1 (0.40) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL20331101 | 0.84 | MEN1 (0.36) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL29577811 | 0.83 | TTK (0.41) | PDE4BPDE4APDE4CPDE4DPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3524603-B1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3524603-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018113584-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海和誉生物医药科技有限公司 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | PDE4B 1559/4885PDE4A 2920/4885PDE4C 3619/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | PDE4B 1559/4885PDE4A 2920/4885PDE4C 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.